IMMUTEP LIMITED - Announcements

Market Cap $428.5M Add to my watchlist

Healthcare Biotechnology

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

IMM	Immutep receives A$686,704 R&D Tax Incentive	PRICE SENSITIVE	05/03/18	204.27KB	Share
IMM	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/18	648.97KB	Share
IMM	Outcome of DSMB Safety Review & Extension of TACTI-mel	PRICE SENSITIVE	09/02/18	439.65KB	Share
IMM	Immutep receives USD1M milestone payment from EOC	PRICE SENSITIVE	01/02/18	344.75KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	22/01/18	107.14KB	Share
IMM	Change of Director's Interest Notice - Russell Howard		22/12/17	801.58KB	Share
IMM	Investor Update		21/12/17	607.77KB	Share
IMM	Operational Update	PRICE SENSITIVE	12/12/17	532.03KB	Share
IMM	Change of Director's Interest Notice - Mr Voigt		04/12/17	440.7KB	Share
IMM	Change of Director's Interest Notice - Mr Chamberlain		04/12/17	478.96KB	Share
IMM	Appendix 3B		04/12/17	312.85KB	Share
IMM	Prima BioMed company name changed to Immutep		28/11/17	479.86KB	Share
IMM	Final Director's Interest Notice		22/11/17	723.47KB	Share
IMM	Final Director's Interest Notice		22/11/17	720.58KB	Share
IMM	European patent grant for IMP321 in cancer	PRICE SENSITIVE	22/11/17	376.58KB	Share
IMM	Prima changes its name to Immutep Ltd		20/11/17	101.69KB	Share
IMM	Results of Meeting		17/11/17	518.22KB	Share
IMM	2017 AGM CEO Presentation		17/11/17	2.57MB	Share
IMM	2017 AGM Chairman's Address		17/11/17	383.95KB	Share
IMM	Pre-IND meeting with the FDA		15/11/17	378.57KB	Share
IMM	SITC 2017 Poster Presentation		09/11/17	115.38KB	Share
IMM	World Immunotherapy Congress 2017 Presentation		01/11/17	437.61KB	Share
IMM	Warrants Cleansing Prospectuses		20/10/17	1.23MB	Share
IMM	Dr Triebel presenting at World Immunotherapy Congress 2017		20/10/17	379.35KB	Share
IMM	Annual Report filed on Form 20-F with SEC		20/10/17	640.25KB	Share
IMM	Notice of Annual General Meeting/Proxy Form		17/10/17	1.4MB	Share
IMM	Annual Report to shareholders		17/10/17	1.28MB	Share
IMM	Appendix 4G & Corporate Governance Statement		17/10/17	1.68MB	Share
IMM	Prima to present at SITC 2017		17/10/17	380.51KB	Share
IMM	Investor Update		11/10/17	2.35MB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	11/10/17	105.17KB	Share
IMM	Change of Director's Interest Notice - Pete Meyers		03/10/17	490.26KB	Share
IMM	Appendix 3B and Cleansing Notice		03/10/17	1.61MB	Share
IMM	Japanese Patent Grant for IMP731 Antibody	PRICE SENSITIVE	08/09/17	379.49KB	Share
IMM	Japanese Patent Grants For IMP321 In Infectious Disease	PRICE SENSITIVE	05/09/17	373.83KB	Share
IMM	PRR & Monash Uni receive funding grant for LAG-3 Research	PRICE SENSITIVE	30/08/17	128.55KB	Share
IMM	Appendix 4E & 2017 Full Year Statutory Accounts	PRICE SENSITIVE	28/08/17	2.28MB	Share
IMM	Appendix 3X		21/08/17	303.79KB	Share
IMM	Appointment of Non-Executive Director		21/08/17	369.87KB	Share
IMM	French government research cash rebate of A$1.3M received	PRICE SENSITIVE	16/08/17	101.43KB	Share
IMM	Change of Director's Interest Notice		07/08/17	440.01KB	Share
IMM	Appendix 3B & Cleansing Notice		07/08/17	224.16KB	Share
IMM	Investor Update		03/08/17	315.53KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	18/07/17	408.2KB	Share
IMM	Financial Update	PRICE SENSITIVE	18/07/17	363.41KB	Share
IMM	2nd milestone payment to be received from Novartis	PRICE SENSITIVE	17/07/17	373.16KB	Share
IMM	Approvals received to initiate INSIGHT clinical trial	PRICE SENSITIVE	10/07/17	375.81KB	Share
IMM	Cleansing Notice		06/07/17	94.42KB	Share
IMM	Disclosure Under LR 3.10.5A and 7.1A.4(b)	PRICE SENSITIVE	06/07/17	105.53KB	Share
IMM	Appendix 3B - USD 5 Million Capital Raising		04/07/17	377.37KB	Share
IMM	Final Prospectus Supplement		03/07/17	394.37KB	Share
IMM	Form 6-K	PRICE SENSITIVE	30/06/17	426.47KB	Share
IMM	Form 6-K	PRICE SENSITIVE	30/06/17	130.73KB	Share
IMM	USD 5 Million Capital Raising	PRICE SENSITIVE	30/06/17	105.91KB	Share
IMM	Preliminary Prospectus Supplement	PRICE SENSITIVE	30/06/17	293.13KB	Share
IMM	Operational Update	PRICE SENSITIVE	26/06/17	388.73KB	Share
IMM	Expiry of Options		07/06/17	73.51KB	Share
IMM	IMP321 demonstrates positive safety & efficacy qualities	PRICE SENSITIVE	05/06/17	109.42KB	Share
IMM	Prima announces formation of new clinical advisory board		01/06/17	401.81KB	Share
IMM	AIPAC phase II clinical trial data to be presented at ASCO		18/05/17	379.96KB	Share
IMM	Approval received to commence 3rd cohort of melanoma trial	PRICE SENSITIVE	19/04/17	374.8KB	Share
IMM	$492k R&D Tax Incentive Refund Received	PRICE SENSITIVE	12/04/17	376.37KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	12/04/17	407.58KB	Share
IMM	Change of Director's Interest Notice - Marc Voigt		16/03/17	37.16KB	Share
IMM	Appendix 3B & Cleansing Notice		16/03/17	221.78KB	Share
IMM	PRR completes recruitment for 2nd patient cohort	PRICE SENSITIVE	15/03/17	92.86KB	Share
IMM	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	10/03/17	177.37KB	Share
IMM	Investor Update		07/03/17	426.75KB	Share
IMM	US patent granted for IMP321	PRICE SENSITIVE	01/03/17	100.51KB	Share
IMM	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/17	1.24MB	Share
IMM	Operational Update	PRICE SENSITIVE	24/02/17	101.83KB	Share
IMM	French Research Tax Credit Payment Received	PRICE SENSITIVE	13/02/17	379.68KB	Share
IMM	Presentation at 2nd Annual Cancer Immunotherapy Conference		23/01/17	110.82KB	Share
IMM	PRR commences randomised phase IIb clinical trial	PRICE SENSITIVE	20/01/17	86.33KB	Share
IMM	Prima BioMed To Maintain NASDAQ Listing		18/01/17	367.55KB	Share
IMM	Prima commences recruitment for 2nd cohort of melanoma trial	PRICE SENSITIVE	12/01/17	87.63KB	Share
IMM	Prima January 2017 Corporate Presentation		06/01/17	1.31MB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	06/01/17	104.93KB	Share
IMM	Prima Enters New MTA with CYTLIMIC	PRICE SENSITIVE	05/01/17	299.14KB	Share
IMM	Prima announces new LAG-3 agonist antibody product candidate	PRICE SENSITIVE	03/01/17	126.53KB	Share
IMM	Prima announces TACTI-mel clinical trial data	PRICE SENSITIVE	29/12/16	377.72KB	Share
IMM	Prima announces AIPAC clinical trial data	PRICE SENSITIVE	22/12/16	377.15KB	Share
IMM	Prima receives UK approval for AIPAC study	PRICE SENSITIVE	20/12/16	100.65KB	Share
IMM	ADR Ratio Change		19/12/16	372.82KB	Share
IMM	Change of Director's Interest Notice		06/12/16	306.38KB	Share
IMM	Appendix 3B		06/12/16	753.82KB	Share
IMM	Appendix 3B		01/12/16	923.86KB	Share
IMM	Results of Meeting		25/11/16	291.37KB	Share
IMM	2016 AGM CEO Presentation		25/11/16	965.36KB	Share
IMM	2016 AGM Address to Shareholders		25/11/16	379.61KB	Share
IMM	Wuxi & Prima sign MOU for strategic partnership	PRICE SENSITIVE	23/11/16	254.5KB	Share
IMM	Investor Update		11/11/16	449.23KB	Share
IMM	Presentation slides for Society for Immunotherapy of Cancer		11/11/16	881.13KB	Share
IMM	Notice of Annual General Meeting/Proxy Form-PRR.AX		25/10/16	1MB	Share
IMM	Appendix 4C - quarterly-PRR.AX	PRICE SENSITIVE	19/10/16	409.27KB	Share
IMM	Prima to present at SITC 2016-PRR.AX		13/10/16	368.67KB	Share
IMM	Abstracts accepted for poster presentation at ESMO-PRR.AX		06/10/16	384.41KB	Share
IMM	Change of Director's Interest Notice-PRR.AX		04/10/16	305.51KB	Share
IMM	Appendix 3B & Cleansing Notice-PRR.AX		04/10/16	679.19KB	Share
IMM	Annual Report filed on Form 20-F with SEC-PRR.AX		04/10/16	922.46KB	Share

IMM Immutep receives A$686,704 R&D Tax Incentive
05/03/18	PRICE SENSITIVE	204.27KB	Share
IMM Half Yearly Report and Accounts
22/02/18	PRICE SENSITIVE	648.97KB	Share
IMM Outcome of DSMB Safety Review & Extension of TACTI-mel
09/02/18	PRICE SENSITIVE	439.65KB	Share
IMM Immutep receives USD1M milestone payment from EOC
01/02/18	PRICE SENSITIVE	344.75KB	Share
IMM Appendix 4C - quarterly
22/01/18	PRICE SENSITIVE	107.14KB	Share
IMM Change of Director's Interest Notice - Russell Howard
22/12/17		801.58KB	Share
IMM Investor Update
21/12/17		607.77KB	Share
IMM Operational Update
12/12/17	PRICE SENSITIVE	532.03KB	Share
IMM Change of Director's Interest Notice - Mr Voigt
04/12/17		440.7KB	Share
IMM Change of Director's Interest Notice - Mr Chamberlain
04/12/17		478.96KB	Share
IMM Appendix 3B
04/12/17		312.85KB	Share
IMM Prima BioMed company name changed to Immutep
28/11/17		479.86KB	Share
IMM Final Director's Interest Notice
22/11/17		723.47KB	Share
IMM Final Director's Interest Notice
22/11/17		720.58KB	Share
IMM European patent grant for IMP321 in cancer
22/11/17	PRICE SENSITIVE	376.58KB	Share
IMM Prima changes its name to Immutep Ltd
20/11/17		101.69KB	Share
IMM Results of Meeting
17/11/17		518.22KB	Share
IMM 2017 AGM CEO Presentation
17/11/17		2.57MB	Share
IMM 2017 AGM Chairman's Address
17/11/17		383.95KB	Share
IMM Pre-IND meeting with the FDA
15/11/17		378.57KB	Share
IMM SITC 2017 Poster Presentation
09/11/17		115.38KB	Share
IMM World Immunotherapy Congress 2017 Presentation
01/11/17		437.61KB	Share
IMM Warrants Cleansing Prospectuses
20/10/17		1.23MB	Share
IMM Dr Triebel presenting at World Immunotherapy Congress 2017
20/10/17		379.35KB	Share
IMM Annual Report filed on Form 20-F with SEC
20/10/17		640.25KB	Share
IMM Notice of Annual General Meeting/Proxy Form
17/10/17		1.4MB	Share
IMM Annual Report to shareholders
17/10/17		1.28MB	Share
IMM Appendix 4G & Corporate Governance Statement
17/10/17		1.68MB	Share
IMM Prima to present at SITC 2017
17/10/17		380.51KB	Share
IMM Investor Update
11/10/17		2.35MB	Share
IMM Appendix 4C - quarterly
11/10/17	PRICE SENSITIVE	105.17KB	Share
IMM Change of Director's Interest Notice - Pete Meyers
03/10/17		490.26KB	Share
IMM Appendix 3B and Cleansing Notice
03/10/17		1.61MB	Share
IMM Japanese Patent Grant for IMP731 Antibody
08/09/17	PRICE SENSITIVE	379.49KB	Share
IMM Japanese Patent Grants For IMP321 In Infectious Disease
05/09/17	PRICE SENSITIVE	373.83KB	Share
IMM PRR & Monash Uni receive funding grant for LAG-3 Research
30/08/17	PRICE SENSITIVE	128.55KB	Share
IMM Appendix 4E & 2017 Full Year Statutory Accounts
28/08/17	PRICE SENSITIVE	2.28MB	Share
IMM Appendix 3X
21/08/17		303.79KB	Share
IMM Appointment of Non-Executive Director
21/08/17		369.87KB	Share
IMM French government research cash rebate of A$1.3M received
16/08/17	PRICE SENSITIVE	101.43KB	Share
IMM Change of Director's Interest Notice
07/08/17		440.01KB	Share
IMM Appendix 3B & Cleansing Notice
07/08/17		224.16KB	Share
IMM Investor Update
03/08/17		315.53KB	Share
IMM Appendix 4C - quarterly
18/07/17	PRICE SENSITIVE	408.2KB	Share
IMM Financial Update
18/07/17	PRICE SENSITIVE	363.41KB	Share
IMM 2nd milestone payment to be received from Novartis
17/07/17	PRICE SENSITIVE	373.16KB	Share
IMM Approvals received to initiate INSIGHT clinical trial
10/07/17	PRICE SENSITIVE	375.81KB	Share
IMM Cleansing Notice
06/07/17		94.42KB	Share
IMM Disclosure Under LR 3.10.5A and 7.1A.4(b)
06/07/17	PRICE SENSITIVE	105.53KB	Share
IMM Appendix 3B - USD 5 Million Capital Raising
04/07/17		377.37KB	Share
IMM Final Prospectus Supplement
03/07/17		394.37KB	Share
IMM Form 6-K
30/06/17	PRICE SENSITIVE	426.47KB	Share
IMM Form 6-K
30/06/17	PRICE SENSITIVE	130.73KB	Share
IMM USD 5 Million Capital Raising
30/06/17	PRICE SENSITIVE	105.91KB	Share
IMM Preliminary Prospectus Supplement
30/06/17	PRICE SENSITIVE	293.13KB	Share
IMM Operational Update
26/06/17	PRICE SENSITIVE	388.73KB	Share
IMM Expiry of Options
07/06/17		73.51KB	Share
IMM IMP321 demonstrates positive safety & efficacy qualities
05/06/17	PRICE SENSITIVE	109.42KB	Share
IMM Prima announces formation of new clinical advisory board
01/06/17		401.81KB	Share
IMM AIPAC phase II clinical trial data to be presented at ASCO
18/05/17		379.96KB	Share
IMM Approval received to commence 3rd cohort of melanoma trial
19/04/17	PRICE SENSITIVE	374.8KB	Share
IMM $492k R&D Tax Incentive Refund Received
12/04/17	PRICE SENSITIVE	376.37KB	Share
IMM Appendix 4C - quarterly
12/04/17	PRICE SENSITIVE	407.58KB	Share
IMM Change of Director's Interest Notice - Marc Voigt
16/03/17		37.16KB	Share
IMM Appendix 3B & Cleansing Notice
16/03/17		221.78KB	Share
IMM PRR completes recruitment for 2nd patient cohort
15/03/17	PRICE SENSITIVE	92.86KB	Share
IMM S&P DJ Indices Announces March Quarterly Rebalance
10/03/17	PRICE SENSITIVE	177.37KB	Share
IMM Investor Update
07/03/17		426.75KB	Share
IMM US patent granted for IMP321
01/03/17	PRICE SENSITIVE	100.51KB	Share
IMM Half Yearly Report and Accounts
24/02/17	PRICE SENSITIVE	1.24MB	Share
IMM Operational Update
24/02/17	PRICE SENSITIVE	101.83KB	Share
IMM French Research Tax Credit Payment Received
13/02/17	PRICE SENSITIVE	379.68KB	Share
IMM Presentation at 2nd Annual Cancer Immunotherapy Conference
23/01/17		110.82KB	Share
IMM PRR commences randomised phase IIb clinical trial
20/01/17	PRICE SENSITIVE	86.33KB	Share
IMM Prima BioMed To Maintain NASDAQ Listing
18/01/17		367.55KB	Share
IMM Prima commences recruitment for 2nd cohort of melanoma trial
12/01/17	PRICE SENSITIVE	87.63KB	Share
IMM Prima January 2017 Corporate Presentation
06/01/17		1.31MB	Share
IMM Appendix 4C - quarterly
06/01/17	PRICE SENSITIVE	104.93KB	Share
IMM Prima Enters New MTA with CYTLIMIC
05/01/17	PRICE SENSITIVE	299.14KB	Share
IMM Prima announces new LAG-3 agonist antibody product candidate
03/01/17	PRICE SENSITIVE	126.53KB	Share
IMM Prima announces TACTI-mel clinical trial data
29/12/16	PRICE SENSITIVE	377.72KB	Share
IMM Prima announces AIPAC clinical trial data
22/12/16	PRICE SENSITIVE	377.15KB	Share
IMM Prima receives UK approval for AIPAC study
20/12/16	PRICE SENSITIVE	100.65KB	Share
IMM ADR Ratio Change
19/12/16		372.82KB	Share
IMM Change of Director's Interest Notice
06/12/16		306.38KB	Share
IMM Appendix 3B
06/12/16		753.82KB	Share
IMM Appendix 3B
01/12/16		923.86KB	Share
IMM Results of Meeting
25/11/16		291.37KB	Share
IMM 2016 AGM CEO Presentation
25/11/16		965.36KB	Share
IMM 2016 AGM Address to Shareholders
25/11/16		379.61KB	Share
IMM Wuxi & Prima sign MOU for strategic partnership
23/11/16	PRICE SENSITIVE	254.5KB	Share
IMM Investor Update
11/11/16		449.23KB	Share
IMM Presentation slides for Society for Immunotherapy of Cancer
11/11/16		881.13KB	Share
IMM Notice of Annual General Meeting/Proxy Form-PRR.AX
25/10/16		1MB	Share
IMM Appendix 4C - quarterly-PRR.AX
19/10/16	PRICE SENSITIVE	409.27KB	Share
IMM Prima to present at SITC 2016-PRR.AX
13/10/16		368.67KB	Share
IMM Abstracts accepted for poster presentation at ESMO-PRR.AX
06/10/16		384.41KB	Share
IMM Change of Director's Interest Notice-PRR.AX
04/10/16		305.51KB	Share
IMM Appendix 3B & Cleansing Notice-PRR.AX
04/10/16		679.19KB	Share
IMM Annual Report filed on Form 20-F with SEC-PRR.AX
04/10/16		922.46KB	Share

REFRESH

First 5 6 7 8 9

(20min delay)
Last 29.5¢		Change 0.000(0.00%)		Mkt cap ! $428.5M

Open	High	Low	Value	Volume
30.0¢	30.5¢	29.0¢	$732.3K	2.454M

Buyers (Bids)

No.	Vol.	Price($)
2	113261	29.5¢

Sellers (Offers)

Price($)	Vol.	No.
30.5¢	169614	3

View Market Depth

No.	Vol.	Price($)
1	13261	0.295
16	654614	0.290
21	379613	0.285
29	1373806	0.280
6	191364	0.275

Price($)	Vol.	No.
0.305	169614	3
0.310	180851	7
0.315	368109	3
0.320	139107	4
0.325	10000	1

Last trade - 16.10pm 22/07/2024 (20 minute delay)


Last 30.0¢		Change 0.000 ( 1.56 %)
Open	High	Low	Volume
30.5¢	30.5¢	29.5¢	811598
Last updated 15.59pm 22/07/2024 ?

IMM (ASX) Chart

IMMUTEP LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available